[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"colorectal-cancer-liver-metastasis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:colorectal-cancer-liver-metastasis":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,42,68,92],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100605171","the-safety-efficacy-and-immune-response-of-multimodal-thermal-therapy-in-the-treatment-of-malignant-liver-tumors-100605171",false,"NCT07159048","The Safety, Efficacy, and Immune Response of Multimodal Thermal Therapy in the Treatment of Malignant Liver Tumors","A Prospective, Multi-center, Randomized Controlled Clinical Trial to Evaluate the Safety, Efficacy and Immune Response of Multimodal Thermal Therapy in the Treatment of Malignant Liver Tumors","Inclusion Criteria:\n\n1. Age of 18-80 years.\n2. Clinical diagnosis or pathologic of hepatocellular carcinoma (HCC) or metastatic liver cancers.\n3. Intrahepatic lesions with a diameter of ≤5cm, and the number of lesions ≤5.\n4. Without extrahepatic metastases; for patients with liver metastases, previously underwent radical resection of the primary lesion without local recurrence.\n5. Child-Pugh score ≤7 (Class A or B).\n6. Performance status 0-1 (Eastern Cooperative Oncology Group classification).\n7. Life expectancy of at least 3 months.\n8. Patients who have previously undergone surgery, chemotherapy, targeted therapy, ablation, vascular interventional therapy (TACE, D-TACE, HAIC), or immunotherapy, with an interval of ≥3 weeks since the last treatment.\n9. The functional level of major organs must meet the following requirements:\n\n(1) Blood Routine: WBC≥3.0×109\u002FL，ANC≥1.5×109\u002FL，PLT≥50×109\u002FL，HGB≥90 g\u002FL. (2) Liver Function: AST ≤5.0×ULN, ALT ≤5.0×ULN, TBIL ≤2.0×ULN. (3) Renal Function: Cr ≤1.5×ULN or CrCl ≥60 mL\u002Fmin. (4) Coagulation Function: INR ≤1.5; APTT ≤1.5×ULN. (5) HBV-DNA: HBV-DNA ≤2×10³ IU\u002FmL (\\*Patients with HBV-DNA \\>2×10³ IU\u002FmL may be enrolled but must receive antiviral therapy.\\*)\n\nExclusion Criteria:\n\n1. Diffuse hepatocellular carcinoma (HCC), or with tumor thrombus in the main portal vein to secondary branches or hepatic veins.\n2. Severe liver atrophy or excessively large tumor volume requiring ablation of ≥1\u002F3 of the liver volume.\n3. Uncorrectable coagulation dysfunction or severe hematologic abnormalities with a high risk of bleeding.\n4. Active bacterial infection or fungal infection.\n5. Previous or coexisting malignancies.\n6. History of solid organ transplant or hepatic encephalopathy.\n7. Current enrollment in another clinical trial or prior exposure to experimental therapies.\n8. Pregnant or breastfeeding, or preparing to pregnant.\n9. Not suitable to participate in clinical trials judged by investigator.","ALL","18 Years","80 Years",{"count":20,"type":21},120,"ESTIMATED","INTERVENTIONAL",[24],"NA","Multimodal thermal therapy (MTT), as an initiative integration of cryotherapy and radiofrequency heating, has been applied to treat various solid tumors. The feasibility and safety for MTT in the treatment of malignant liver tumors is well-established. This prospective, multi-center, randomized controlled clinical study aimed to explore the ablation-induced immune activating response of MTT in the treatment of malignant liver tumors.",[27,28],"Hepatocellular Carcinoma","Colorectal Cancer Liver Metastasis","RECRUITING","2026-08-06",{"date":32,"type":33},"2026-08-10","ACTUAL",{"date":35,"type":33},"2025-10-15",{"date":37,"type":21},"2027-10-31",{"name":39,"class":40},"Fudan University","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":53,"conditions":54,"keywords":55,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":64,"leadSponsor":66,"locationsCount":41},"100623125","prospective-validation-of-an-ai-model-for-predicting-liver-metastasis-in-colorectal-cancer-100623125","NCT07392567","Prospective Validation of an AI Model for Predicting Liver Metastasis in Colorectal Cancer","A Multicenter, Prospective, Observational Study for the Validation of a Multimodal Deep Learning Model to Predict Metachronous Liver Metastasis in Patients With Colorectal Cancer After Curative Resection","Inclusion Criteria:\n\n* Age 18-75 years, any gender.\n* Clinical diagnosis of primary colon or rectal adenocarcinoma (Stage I-III). Scheduled to undergo curative radical resection for colorectal cancer.\n* Preoperative contrast-enhanced abdominal\u002Fpelvic CT scan performed within 1 month before surgery, with acceptable image quality.\n* No evidence of distant metastasis (including synchronous liver metastasis) on preoperative examination.\n* ECOG Performance Status of 0 or 1.\n* Patient or their legal representative voluntarily participates and provides written informed consent.\n\nExclusion Criteria:\n\n* Postoperative pathological confirmation of non-primary colorectal adenocarcinoma or presence of distant metastasis.\n* Intraoperative determination of non-R0 resection, or performance of palliative surgery\u002Fostomy only.\n* History of other malignant tumors.\n* Previous history of liver surgery or liver transplantation.\n* Death within the perioperative period (within 30 days after surgery).\n* Refusal to participate in follow-up, withdrawal of informed consent, or loss to follow-up.","75 Years",{"count":51,"type":21},160,"OBSERVATIONAL","This is a prospective, multicenter, observational study designed to validate the predictive accuracy of a pre-developed multimodal deep learning model. The model integrates preoperative contrast-enhanced CT scans, digitized postoperative pathology images, and standard clinical data to estimate the risk of liver metastasis within two years after curative surgery in patients with stage I-III colorectal cancer.\n\nThe primary objective is to evaluate the model's performance in an independent, prospectively enrolled patient cohort. Participants will receive standard-of-care treatment according to clinical guidelines. The study involves no experimental interventions; it solely involves the collection and analysis of routinely generated clinical data. The goal is to assess the model's potential for clinical translation by providing a reliable tool for stratifying patients' risk of liver metastasis, which could inform personalized surveillance strategies.",[28],[56,57,58,59],"colorectal cancer liver metastasis","deep learning","multimodal","predictive model","2026-01-30",{"date":62,"type":33},"2026-02-06",{"date":60,"type":33},{"date":65,"type":21},"2029-01-30",{"name":67,"class":40},"Tongji Hospital",{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":49,"enrollmentInfo":75,"targetDuration":4,"studyType":22,"phases":77,"briefSummary":79,"conditions":80,"keywords":4,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":41},"100576659","phase-2-pulsar-combined-with-pd-1-ab-and-chemotherapy-plus-bev-for-crlm-100576659","NCT06788171","PULSAR Combined With PD-1 Ab and Chemotherapy Plus Bev. for CRLM","A Phase II Trial of PULSAR (Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy) Combined With PD-1 Ab and Chemotherapy Plus Bevacizumab for Colorectal Cancer Liver Metastasis","Inclusion Criteria:\n\n1. Age 18-75 years, any gender.\n2. Pathologically confirmed colorectal cancer with liver metastases (stage M1).\n3. Karnofsky Performance Status ≥70.\n4. Adequate organ function, no contraindications to radiotherapy, or immunotherapy.\n5. Microsatellite\u002Fmismatch repair status MSS\u002FpMMR.\n6. No prior chemotherapy or any other anti-tumor treatment before inclusion.\n7. No prior immunotherapy.\n8. Ability to comply with the study protocol during the study period.\n9. Signed written informed consent.\n\nExclusion Criteria:\n\n1. Pregnant or lactating women.\n2. Pathological diagnosis of signet ring cell carcinoma.\n3. History of other malignancies within the past 5 years, except cured skin cancer and cervical carcinoma in situ.\n4. Uncontrolled epilepsy, central nervous system disorders, or history of psychiatric disorders that, in the opinion of the investigator, may interfere with signing the informed consent form or affect patient compliance with oral medication.\n5. Clinically significant (i.e., active) cardiac disease, such as symptomatic coronary artery disease, New York Heart Association (NYHA) Class II or greater congestive heart failure, or significant arrhythmias requiring drug intervention (see Appendix 12), or history of myocardial infarction within the past 12 months.\n6. Organ transplant recipients requiring immunosuppressive therapy and long-term steroid users.\n7. Patients with autoimmune diseases.\n8. Severe uncontrolled recurrent infections or other severe uncontrolled comorbidities.\n9. Subjects with baseline hematological and biochemical parameters not meeting the following criteria: hemoglobin ≥90g\u002FL; absolute neutrophil count (ANC) .≥1.5×10\\^9\u002FL; platelets ≥100×10\\^9\u002FL; ALT, AST ≤2.5 times the upper limit of normal; ALP ≤2.5 times the upper limit of normal; serum total bilirubin \\\u003C1.5 times the upper limit of normal; serum creatinine \\\u003C1 times the upper limit of normal; serum albumin ≥30g\u002FL.\n10. Known deficiency of dihydropyrimidine dehydrogenase (DPD).\n11. Allergy to any investigational drug components.",{"count":76,"type":21},35,[78],"PHASE2","To explore Progression-Free-Survival(FPS) of PULSAR(personalized ultrafractionated stereotactic adaptive radiotherapy) combined with PD-1 Ab and Chemotherapy plus Bevacizumabfor CRLM",[28],"NOT_YET_RECRUITING","2025-01-18",{"date":84,"type":33},"2025-01-23",{"date":86,"type":21},"2025-03-01",{"date":88,"type":21},"2026-12-01",{"name":90,"class":91},"Fujian Cancer Hospital","OTHER_GOV",{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":49,"enrollmentInfo":99,"targetDuration":4,"studyType":22,"phases":101,"briefSummary":102,"conditions":103,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":41},"100561445","phase-2-a-study-on-the-efficacy-and-safety-of-multi-mode-ablation-combined-with-systemic-therapy-in-the-treatment-of-crclm-100561445","NCT06590259","A Study on the Efficacy and Safety of Multi-mode Ablation Combined With Systemic Therapy in the Treatment of CRCLM","A Study on the Efficacy and Safety of Multi-mode Ablation Combined With Systemic Therapy Including PD-1 Inhibitor in the Treatment of Colorectal Cancer Liver Metastasis(CRCLM)","Inclusion Criteria:\n\n1. Age 18-75 years, gender not specified;\n2. Pathologically or clinically confirmed colorectal cancer liver metastases, with liver lesions unsuitable for surgical resection or intolerance or refusal of surgical resection;\n3. In the case of an unresectable primary tumor or recurrence, the absence of serious complications such as bleeding or obstruction;\n4. Failure of first-line treatment, with disease progression or new liver metastases;\n5. No more than 5 liver lesions, with single lesion diameter ≤ 3cm;\n6. For those who have received previous chemotherapy, radiotherapy or local liver treatment, the interval from the last systemic treatment or local liver treatment should be at least 1 month;\n7. Child-Pugh A or B; bilirubin ≤ 3.0 mg\u002FdL, creatinine ≤ 2.5 mg\u002FdL, white blood cell count ≥ 2.0 ×10\\^9\u002FL, platelets ≥ 100 ×10\\^9\u002FL;\n8. ECOG PS ≤ 2;\n9. Willing to accept subsequent treatment regimens that include anti-PD-1 monoclonal antibody therapy.\n\nExclusion Criteria:\n\n1. Liver function Child-Pugh class C;\n2. Expected survival \\\u003C 3 months;\n3. Major organ insufficiency or failure;\n4. Active infection;\n5. Irreversible coagulation disorders;\n6. Refractory massive ascites, pleural effusion or cachexia;\n7. Unable to cooperate with treatment;\n8. Any other factors deemed inappropriate for inclusion or that may affect the subject's participation in the study, as determined by the investigator.",{"count":100,"type":21},20,[78],"The goal of this study is to evaluate the efficacy and safety of multi-mode ablation combined with systemic therapy including PD-1(programmed death receptor 1) inhibitor for colorectal cancer liver metastasis and furthermore to clarify its application value by comparing preoperative and postoperative immune indicators.",[28],"2024-09-09",{"date":106,"type":33},"2024-09-19",{"date":108,"type":33},"2024-03-12",{"date":110,"type":21},"2027-12",{"name":112,"class":40},"Shanghai 6th People's Hospital"]